GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

(Reuters) -GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

GSK Plc (NYSE:GSK) stock fell 5% after a U.S. Food and Drug Administration advisory panel voted against recommending approval for its blood cancer drug Blenrep, citing concerns that risks outweigh ...

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

GSK (NYSE: GSK) announced ... a type of blood cancer. ... However, months later GSK renewed its bid to market the drug, and the EMA accepted its marketing authorization application in July 2024.

GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs Concerns about the company’s vaccines business have weighed on its share price, heightened by vaccine skepticism in the U.S. administration By ...